$DRMA Income Statement | Understand Stock

$DRMA

$0.87 +$0.12 (15.85%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating expenses:
Research and development
General and administrative
Selling, general and administrative (including related party amounts of $645,250 and $0, respectively)
Total operating expenses
Loss from operations
Other income and expenses:
Gain from forgiveness of Paycheck Protection Plan loan
Interest expense, net
Interest (income) expense, net
Interest income
Interest income
Net loss
Series 1d convertible preferred stock
Deemed dividend upon the redemption of 5,221,156 shares of Series 1c preferred stock (see Note 6)
Deemed dividend upon the amendment of terms of the Series 1d convertible preferred stock (see Note 6)
Net loss attributable to common stockholders
Net loss per share of common stock, basic and diluted
Weighted-average basic and diluted common shares
Net loss per share of Common Stock, basic
Net loss per share of Common Stock, diluted
Weighted-average basic Common Stock
Weighted-average diluted Common Stock

Comments